Ciprofloxacin-Novofarm To the previous page

Marketing Authorization

Pharmaceutical form

Solution for infusion.
Main physical and chemical properties: clear yellowish or yellowish-green solution.

Pharmacotherapeutic group

Antibacterial agents for systemic use. Fluoroquinolones group. Ciprofloxacin. ATC Code J01М А02.

Therapeutic indications

• Lower respiratory tract infections caused by Gram-negative bacteria:
– exacerbation of chronic obstructive pulmonary disease*;
– bronchopulmonary infections with cystic fibrosis or bronchiectasis;
– community acquired pneumonia.
• Chronic purulent otitis media.
• Exacerbation of chronic sinusitis, especially if caused by Gram-negative bacteria*.
• Infections of the urinary tract:
– uncomplicated acute cystitis*;
– acute pyelonephritis;
– complicated urinary tract infections;
– bacterial prostatitis.
• Infections of the genital tract:
– gonococcal urethritis and cervicitis caused by Neisseria gonorrhoeae;
– orchiepididymitis, particularly those caused by Neisseria gonorrhoeae;
– pelvic inflammatory diseases, particularly those caused by Neisseria gonorrhoeae.
In the above-mentioned genital tract infections, when Neisseria gonorrhoeae is known or suspected to be the causative agent, it is especially important to obtain local information about ciprofloxacin resistance and to confirm sensitivity on the basis of laboratory tests.
• Gastrointestinal tract infections (e.g., treatment of traveler’s diarrhea).
• Intra-abdominal infections.
• Skin and soft tissue infections caused by Gram-negative bacteria.
• Bone and joint infections.
• Pulmonary anthrax (post-exposure prevention and radical treatment).
• Fever in patients with neutropenia caused by bacterial infection.
Children and adolescents.
• Bronchopulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis.
• Complicated urinary tract infections and acute pyelonephritis.
• Pulmonary anthrax (post-exposure prevention and radical treatment).
Ciprofloxacin can also be used to treat severe infections in children and adolescents when doctor deems it necessary.
Treatment should only be started by a doctor experienced in treating the above infections in children and adolescents.
*Only if other antibacterial agents normally prescribed for the treatment of this infection are found to be ineffective or inappropriate.


100 mL or 200 mL in glass bottles.

Sales market


Download the instruction